$SPRO Cashflow Statement | Understand Stock

$SPRO

$1.14 +$0.07 (6.54%) Close

$SPRO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization
Non-cash lease cost
Impairment of assets
Share-based compensation
Unrealized foreign currency transaction (gain) loss
Accretion of premium (discount) on marketable securities
Change in fair value of derivative liabilities
Non-cash interest expense associated with the sale of future royalties
Loss on extinguishment of liability related to the sale of future royalties
Changes in operating assets and liabilities:
Collaboration receivable, current and non-current - related party
Other receivables
Prepaid expenses and other current assets
Tax incentive receivables
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Deferred revenue - related party
Other long-term liabilities
Operating lease liabilities
Income taxes payable

Net cash used in operating activities
Purchases of marketable securities
Proceeds from maturities of marketable securities
other
Net cash provided by investing activities
Cash flows from financing activities:
Repayment of liability related to the sale of future royalties
Proceeds from the issuance of common stock, net of issuance costs
Proceeds from the issuance of common stock, net of commissions
Proceeds from the issuance of common stock related to the GSK Share Purchase Agreement
Pfizer Purchase Agreement
Total proceeds from the issuance of common stock, net of issuance costs

Proceeds from sale of future royalties, net
Transaction costs from sale of future royalties
Royalty payments
Proceeds from stock option exercises
Net cash provided by financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information
Right-of-use assets and lease obligations recorded upon commencement or amendment of lease agreements
Cash paid for income taxes

Comments